Orphaning Biotech? The Impact of Biosimilars on Biotech Investment
This article was originally published in RPM Report
Executive Summary
An abbreviated follow-on biologics pathway is inevitable, despite the fact that Congress failed to pass legislation in 2007. Will a FOBs pathway adversely impact money flowing into the biotech industry? Unlikely. The impact of the 1983 Orphan Drug Act may be a good model to consider.